SEC Form 4 · accession 0001179110-18-010637
Theravance Biopharma, Inc. · TBPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Renee D Gala
Officer — SVP, Chief Financial Officer
Period of report
Aug 14, 2018
Accepted (ET)
Aug 16, 2018 · 7:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001583107
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Aug 14, 2018 | S | 2,204 | $27.7386 | D | 212,588 | D | |
| Ordinary SharesF2 | Aug 15, 2018 | S | 39,839 | $26.7083 | D | 172,749 | D | |
| Ordinary SharesF3 | Aug 15, 2018 | S | 1,700 | $27.4254 | D | 171,049 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades at prices from $27.515 to $28.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
- F2This transaction was executed in multiple trades at prices from $26.265 to $27.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices from $27.27 to $27.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.